IP Appeals Court Shifts To Plain Meaning, Summary Judgement Reversals
This article was originally published in The Gray Sheet
The federal appeals court is increasing its preference of construing claims based on "plain meaning" over the "doctrine of equivalents" in intellectual property litigation, potentially benefiting defendants in medical device patent litigation, according to IP attorneys
You may also be interested in...
Bare-metal stent intellectual property litigation between Johnson & Johnson/Cordis and Medtronic AVE presented before the Washington, D.C. federal appeals court May 6 hinges on the manufacturing method used to create holes in the devices
Opposing patent infringement claims by Boston Scientific and Johnson & Johnson introduce a level of uncertainty as to which firm will initially capture the lion's share of the U.S. drug-eluting stent market
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.